Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

PD-L1-specific T cells

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Cancer immunotherapy in patients with brain metastases

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Exercise and cancer: from "healthy" to "therapeutic"?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Broadening the repertoire of melanoma-associated T-cell epitopes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Terapeutisk cancervaccination mod hæmatologisk cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Inflammation induced PD-L1-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Expression and function of Kv1.3 channel in malignant T cells in Sézary syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies. We have described naturally occurring PD-L1-specific T cells that recognize both PD-L1-expressing immune cells and malignant cells. Thus, PD-L1-specific T cells have the ability to modulate adaptive immune reactions by reacting to regulatory cells. Thus, utilization of PD-L1-derived T cell epitopes may represent an attractive vaccination strategy for targeting the tumor microenvironment and for boosting the clinical effects of additional anticancer immunotherapy. This review summarizes present information about PD-L1 as a T cell antigen, depicts the initial findings about the function of PD-L1-specific T cells in the adjustment of immune responses, and discusses future opportunities.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy : CII
Vol/bind65
Udgave nummer7
Sider (fra-til)797-804
ISSN0340-7004
DOI
StatusUdgivet - 2 jan. 2016

ID: 45949544